Bigul

Medico Remedies Ltd - 540937 - Statement Of Investor Complaints For The Quarter Ended June 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshit MehtaDesignation :- Director
09-07-2019
Bigul

Medico Remedies Ltd - 540937 - Results - Audited Financial Results For The Half Year Ended 31St March 2019 And Audited Financial Statements For The Year Ended 31St March, 2019 And Auditor''s Report Thereon.

Audited Financial Results for the half year ended 31st March 2019 and Audited Financial Statements for the year ended 31st march, 2019 and Auditor''s Report thereon.
25-05-2019
Bigul

Medico Remedies Ltd - 540937 - Outcome of Board Meeting

Pursuant to Regulation 30 of SEBI (LODR), Regulations, 2015, we hereby inform you that the Meeting of Board of Directors of MEDICO REMEDIES LIMITED held today i.e. 25th May, 2019 has, inter alia considered and approved the Audited Standalone Financial Results of the Company for the half year ended 31st March, 2019 and Audited Financial Statements for the year ended on 31st March, 2019 along with the Auditor's Report thereon. Kindly take the same on record.
25-05-2019
Bigul

Medico Remedies Ltd - 540937 - Board Meeting Intimation for To Consider And Approve The Audited Financial Results For The Half Year And Audited Financial Statements For The Year Ended 31St March, 2019 And To Take Note Of The Auditor''s Report Thereon.

Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2019 ,inter alia, to consider and approve the Audited Financial Results for the half year and Audited Financial Statements for the year ended 31st March, 2019 and to take note of the Auditor''s Report thereon.
17-05-2019
Bigul

Medico Remedies Ltd - 540937 - Fund Raising By Issuance Of Debt Securities By Large Entities.

Pursuant to BSE Circular No. LIST/COMP/05/2019-20 dated April 11, 2019, read with SEBI Circular No.SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, in respect of fund raising by issuance of debt securities by large entities, we hereby submit that our Company does not fall under the Large Corporate category as defined in the aforesaid SEBI Circular.
30-04-2019
Bigul

Medico Remedies Ltd - 540937 - Compliance Certificate For The Half Year Ended On 31-03-2019 Pursuant To Regulation 7(3) Of The SEBI (LODR) Regulations, 2015.

We hereby submit the duly signed Compliance Certificate for the half year ended on 31-03-2019 pursuant to Regulation 7(3) of the SEBI (LODR) Regulations, 2015.
27-04-2019
Bigul

Medico Remedies Ltd - 540937 - Certificate U/R 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019.

We hereby submit Certificate issued by Practising Company Secretary u/r 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended on 31st March, 2019.
27-04-2019
Bigul

Medico Remedies Ltd - 540937 - Shareholding for the Period Ended March 31, 2019

Medico Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here
20-04-2019
Bigul

Medico Remedies Ltd - 540937 - Statement Of Investor Complaints For The Quarter Ended March 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshit MehtaDesignation :- Director
18-04-2019
Bigul

Medico Remedies Ltd - 540937 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

Pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, please find enclosed the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information along with Policy for Determination of "Legitimate Purposes", forming part of it ("Code").
03-04-2019
Next Page
Close

Let's Open Free Demat Account